Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer
Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Chemoembolization kills tumor cells by blocking the blood flow to the tumor and
keeping anticancer drugs near the tumor. Sunitinib malate may stop the growth of tumor cells
by blocking some of the enzymes needed for cell growth and by blocking blood flow to the
tumor. It is not yet known whether chemoembolization is more effective with or without
sunitinib malate in treating patients with liver cancer.
PURPOSE: This randomized phase II/III trial is studying the side effects of chemoembolization
of the liver and to see how well in works when given together with or without sunitinib
malate in treating patients with liver cancer.